Phase III
KEYNOTE-A18 Trial: Primary Endpoint – Progression-Free Survival in High-Risk Cervical Cancer
SG Tylor
Source – Merck Merck has announced a groundbreaking development in its Phase III KEYNOTE-A18 trial, also referred to as ENGOT-cx11/GOG-3047. ...
BridgeBio Reports Improved Data for ATTR Cardiomyopathy Drug
SG Tylor
Source – BridgeBio BridgeBio is preparing to seek FDA approval for its acoramidis drug to treat transthyretin amyloidosis (ATTR) cardiomyopathy, ...
J&Jās Rybrevant Wins in Rare Lung Cancer; Awaits Tagrisso Showdown
SG Tylor
Source – Johnson & Johnson In 2021, Johnson & Johnson’s Rybrevant received accelerated approval from the FDA, becoming the first ...
Skyrizi from AbbVie wins a maintenance trial for ulcerative colitis and is poised to receive FDA approval
SG Tylor
Source – Abbvie On 16 June 2023, Risankizumab (SKYRIZI, 180 mg or 360 mg subcutaneous [SC]) achieved the primary endpoint ...
